|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021083,
umls-concept:C0030705,
umls-concept:C0079731,
umls-concept:C0085101,
umls-concept:C0205269,
umls-concept:C0282440,
umls-concept:C0393022,
umls-concept:C0439682,
umls-concept:C0877880,
umls-concept:C1096777,
umls-concept:C1510411
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2002-5-15
|
|
pubmed:abstractText |
Radioimmunotherapy combines biologic and radiolytic mechanisms to target and destroy tumor cells, thus offering a needed therapeutic alternative for refractory non-Hodgkin's lymphoma (NHL) patients. This phase III randomized study compares the novel radioimmunotherapy yttrium-90 ((90)Y) ibritumomab tiuxetan with a control immunotherapy, rituximab, in 143 patients with relapsed or refractory low-grade, follicular, or transformed CD20(+) transformed NHL.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BartlettNancy LNL,
pubmed-author:CabanillasFernandoF,
pubmed-author:CzuczmanMyron SMS,
pubmed-author:EmmanouilidesChristosC,
pubmed-author:GordonLeo ILI,
pubmed-author:Grillo-LópezAntonio JAJ,
pubmed-author:JoyceRobinR,
pubmed-author:MultaniPratikP,
pubmed-author:PadreNormanN,
pubmed-author:PohlmanBrad LBL,
pubmed-author:WhiteChristine ACA,
pubmed-author:WisemanGregory AGA,
pubmed-author:WitzigThomas ETE
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2453-63
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12011122-Adult,
pubmed-meshheading:12011122-Aged,
pubmed-meshheading:12011122-Aged, 80 and over,
pubmed-meshheading:12011122-Antibodies, Monoclonal,
pubmed-meshheading:12011122-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:12011122-Antigens, CD19,
pubmed-meshheading:12011122-Antineoplastic Agents,
pubmed-meshheading:12011122-Cell Transformation, Neoplastic,
pubmed-meshheading:12011122-Disease Progression,
pubmed-meshheading:12011122-Disease-Free Survival,
pubmed-meshheading:12011122-Female,
pubmed-meshheading:12011122-Humans,
pubmed-meshheading:12011122-Liver,
pubmed-meshheading:12011122-Lymphoma, B-Cell,
pubmed-meshheading:12011122-Lymphoma, Follicular,
pubmed-meshheading:12011122-Lymphoma, Non-Hodgkin,
pubmed-meshheading:12011122-Male,
pubmed-meshheading:12011122-Middle Aged,
pubmed-meshheading:12011122-Radioimmunotherapy,
pubmed-meshheading:12011122-Survival Rate,
pubmed-meshheading:12011122-Treatment Outcome,
pubmed-meshheading:12011122-Yttrium Radioisotopes
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Division of Internal Medicine and Hematology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, 60 Stabile Building, Rochester, MN 55905, USA. witzig@mayo.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
